3E Acquires Workplace Safety Provider, Quick-FDS
3E, the leading global provider of intelligent compliance solutions for chemical and workplace safety, product stewardship, and sustainable supply chains, has completed its previously announced acquisition of Quick-FDS, the leading provider of workplace safety solutions in France. The acquisition of Quick-FDS from WEKA Group further expands 3E’s presence in Europe and establishes a leading position in the French market in particular.
Quick-FDS partners with both global manufacturers and downstream users of chemical products, providing mission-critical solutions that enable improved regulatory compliance and workplace safety. The Company has developed a highly specialized knowledge base and resource library of Safety Data Sheets (“SDS”), allowing many of the world’s largest companies to comply with both local and global regulatory pressures.
“We are thrilled to welcome Quick-FDS’ team, clients and partners into the broader 3E organization. Expanding in the French market has been a high priority for 3E and we are excited to accelerate our growth in the country through the combination of two industry-leading businesses,” said Greg Gartland, Chief Executive Officer of 3E. “This combination further solidifies 3E as the global leader in SDS management, empowering clients to improve chemical and workplace safety in a world with increasingly complex regulations.”
Deep knowledge and understanding of continuously evolving regulations have become critical for companies in and adjacent to the chemical industry. REACH regulations in the EU require all suppliers of chemicals to provide a unique Safety Data Sheet for each chemical substance to their customers. Quick-FDS’ market-leading solution enables compliance with REACH and a variety of other EU regulations, allowing customers to execute on their strategic goals while adhering to increasingly stringent requirements.
Robin Dualé, Managing Director of WEKA Group in France, said “This combination represents a significant milestone in the EHS&S industry, bringing together two of the most sophisticated providers of SDS management, workplace safety, and product stewardship solutions in Europe. The breadth of solutions that the combined company will be able to provide to clients is unparalleled, allowing for more informed decisions while reducing regulatory risks consistently, efficiently, and confidently.”
“This combination is highly strategic as 3E continues to expand its presence in Europe and across the globe,” added JP O'Sullivan, Chief Operating Officer at 3E. "With the combined strengths and capabilities of both 3E and Quick-FDS, we remain deeply committed to offering safety and compliance solutions to our clients and will be able to provide greater value and expertise as we serve an expanding global customer base."
3E has been active in strategic acquisition efforts since its separation from Verisk, having acquired Toxnot, Chemycal, ChemChain, and now Quick-FDS since March of 2022.
Shearman & Sterling LLP and Proskauer Rose LLP serve as the legal advisors to 3E. WEKA Group and Quick-FDS are advised by Carlsquare (M&A) and Astura (Legal).
About Quick-FDS
Quick-FDS provides digital workflow solutions related to Safety Data Sheet management to help manufacturers and end-users along the full supply chain for chemical products comply with global regulations, including European REACH. Quick-FDS’ historical success is driven by tight integration with compliance-related workflows throughout the chemical and specialty materials sector. Global chemical manufacturers, distributors, and wholesalers strongly endorse Quick-FDS as a true partner within their broader regulatory strategy.
About 3E
For more than 35 years the world’s leading companies have trusted 3E to provide the intelligent compliance solutions they need to ensure safety and sustainability. Unmatched Environmental, Health, Safety and Sustainability (EHS&S) and product compliance expertise empowers clients to improve chemical and workplace safety, product safety and stewardship and supply chain transparency. 3E is deeply committed to serving its more than 5,000 customers worldwide, representing a wide variety of industries and including the world’s largest chemical manufacturers, retailers and pharmaceutical companies. Learn more at www.3Eco.com
About WEKA Group
WEKA Group is a diversified group of media companies and a leading provider of specialist information and advanced education with 15 operational companies in Germany, Austria, and France. WEKA Group’s media-neutral content is offered in all common formats and reaches highly diversified niche markets across all industries. WEKA Group is headquartered in Kissing, Germany, and employs approximately 1,000 employees.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240328295790/en/
Contact information
Media:
Maria Rutland
3E
maria.rutland@3eco.com
+1.760.987.5152
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aesyra Demonstrates Significant Sleep Bruxism Reduction in Clinical Study26.1.2026 10:00:00 EET | Press release
Aesyra SA, a Swiss medtech company developing innovative digital therapeutics for dental and sleep-related disorders, today announced the successful completion of its clinical investigation evaluating the efficacy and safety of AesyBite™ Active, an intelligent oral appliance designed to treat and prevent sleep bruxism through biofeedback. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126533019/en/ AesyBite Custom smart nightguard by Aesyra SA. The clinical investigation demonstrated that AesyBite™ Active achieved a statistically significant and clinically meaningful reduction in sleep bruxism activity, exceeding the predefined performance target. Strong and robust clinical outcomes In the study (Identifier: NCT06153810), involving 26 adult patients with confirmed sleep bruxism, activation of the AesyBite Active biofeedback system resulted in a 60.6% reduction in total sleep bruxism duration per hour compared to baseline
Franklin Templeton Aligns Alternative Credit Firms Under BSP Brand26.1.2026 09:58:00 EET | Press release
Franklin Templeton’s US and European alternative credit businesses, Benefit Street Partners and Alcentra, have now aligned under an updated Benefit Street Partners (BSP) brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260123270080/en/ David Manlowe, CEO of Benefit Street Partners The move is the final step in BSP and Alcentra’s integration – two pioneering alternative credit firms that Franklin Templeton acquired in 2019 and 2022, respectively – and reflects increasing investor demand for a specialist global credit platform with expertise across the full spectrum of the asset class. A refreshed logo and new website domain accompany the brand alignment, and from this week Alcentra branded funds start to take on the BSP name.1 Overall, Franklin Templeton’s alternative credit platform – which also includes direct lender Apera – is on track to exceed $100 billion in AUM in 2026. According to new research also published tod
Syngenta and Statkraft Sign Five-Year Virtual Power Purchase Agreement26.1.2026 09:00:00 EET | Press release
Syngenta, one of the world’s biggest agricultural innovation companies, and Statkraft, a leading provider of innovative green energy solutions in Europe, have signed a virtual power purchase agreement (vPPA) covering Syngenta’s CP & Seeds operations for a period of five years. The volume amounts to 125 GWh per year and a total of 625 GWh of green electricity by the end of the contract in 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260125701845/en/ Syngenta and Statkraft sign five-year virtual power purchase agreement With the vPPA, Statkraft is supporting Syngenta in advancing its sustainability strategy through the purchase of renewable energy. "This is Syngenta's first vPPA, marking a pivotal step in our decarbonization strategy," said Rachel Stenson Bugnon, Global Head CP Sourcing at Syngenta. "This tailored approach allows us to make meaningful progress toward our carbon reduction targets for Syngenta AG while m
Samsung Epis Holdings Reports Fourth Quarter and Fiscal Year 2025 Financial Results26.1.2026 09:00:00 EET | Press release
Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced financial results for the fourth quarter and fiscal year 2025. “We are very pleased to report strong year-to-date sales growth in our first financial results following the spin-off. Our organic growth has been driven by solid performance across our biosimilars portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are continuing to make meaningful progress in our regulatory and commercial milestones with our existing biosimilars portfolio, while strategically investing in our future pipeline with a disciplined, long-term approach. We aim to drive sustainable growth and create long-term value for our shareholders, so that we can remain committed to improving patient access worldwide.” Samsung Bioepis Fourth Quarter & Fiscal Year 2025 Results In the fourth quarter of 2025, Samsung Bioepis achieved a
Merz Therapeutics Submits Application to the European Medicines Agency for New Indication of XEOMIN ® in Pediatric Spasticity26.1.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that it has completed the regulatory submission for XEOMIN® (incobotulinumtoxinA) for the treatment of spasticity of the lower and upper limb in children and adolescents aged 2–17 years in the European Union (EU) and European Economic Area (EEA). If approved, the indication would expand access to an established botulinum neurotoxin therapy for some of the youngest and most vulnerable patients across Europe. Spasticity is a common and often debilitating condition in children and adolescents with certain neurological conditions, leading to increased muscle tone that can significantly limit movement, function and independence. One of the most common underlying causes of spasticity in children is cerebral palsy (CP), the most frequent motor disability in childhood, with spastic forms accounting for approximately 80% of all cases. In more severe cases, spasticity associated with CP can also affect spe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom